Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Debt (2018 - 2022)

Sutro Biopharma (STRO) has disclosed Non-Current Debt for 5 consecutive years, with $3.8 million as the latest value for Q4 2022.

  • Quarterly Non-Current Debt fell 76.04% to $3.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2022, down 76.04% year-over-year, with the annual reading at $3.8 million for FY2022, 76.04% down from the prior year.
  • Non-Current Debt hit $3.8 million in Q4 2022 for Sutro Biopharma, down from $6.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $24.7 million in Q1 2021 to a low of $3.8 million in Q4 2022.
  • Historically, Non-Current Debt has averaged $14.6 million across 5 years, with a median of $12.1 million in 2018.
  • Biggest five-year swings in Non-Current Debt: surged 343.84% in 2020 and later tumbled 76.04% in 2022.
  • Year by year, Non-Current Debt stood at $10.0 million in 2018, then decreased by 11.24% to $8.9 million in 2019, then surged by 176.53% to $24.5 million in 2020, then tumbled by 35.88% to $15.7 million in 2021, then crashed by 76.04% to $3.8 million in 2022.
  • Business Quant data shows Non-Current Debt for STRO at $3.8 million in Q4 2022, $6.8 million in Q3 2022, and $9.8 million in Q2 2022.